-
公开(公告)号:US20240287058A1
公开(公告)日:2024-08-29
申请号:US17921580
申请日:2021-04-29
Applicant: Relay Therapeutics, Inc. , D. E. Shaw Research, LLC
Inventor: Alessandro BOEZIO , Lucian V. DIPIETRO , Cary Griffin FRIDRICH , Hakan GUNAYDIN , Ravi KURUKULASURIYA , André LESCARBEAU , Mary M. MADER , Thomas H. MCLEAN , Levi CharlesThomas PIERCE , Kevin David RAYNOR , Kelley C. SHORTSLEEVES , Yong TANG , Alexander M. TAYLOR , W. Patrick WALTERS , Hanmo ZHANG , Fabrizio GIORDANETTO , Yakov PECHERSKY , Qi WANG , Bren-Jordan ATIENZA , Megan BERTRAND-LAPERLE , Andrew J. BURNIE , Fei CHEN , Sampada CHITALE , Shorena GELOZIA , Jean-Benoit GIGUERE , Elodie LANDAGARAY , Alexandre LARIVEE , Thomas LEPITRE , Gaetan MAERTENS , Johanne OUTIN , Mohan PAL , Claudio STURINO , Kashif TANVEER , Rakesh THORAT , Naresh VEMULA , Elaine B. KRUEGER , Yue PAN , Michael Paul DENINNO , Yves BOUSQUET , Antoine JOBIN-DES LAURIERS , Jessica LEE , Tarek MOHAMED
IPC: C07D471/04 , A61K31/4035 , A61K31/404 , A61K31/4155 , A61K31/416 , A61K31/428 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/472 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/536 , A61K31/69 , C07D209/46 , C07D209/48 , C07D217/24 , C07D231/56 , C07D239/82 , C07D265/18 , C07D275/06 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/06 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D519/00 , C07F5/02
CPC classification number: C07D471/04 , A61K31/4035 , A61K31/404 , A61K31/4155 , A61K31/416 , A61K31/428 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/472 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/536 , A61K31/69 , C07D209/46 , C07D209/48 , C07D217/24 , C07D231/56 , C07D239/82 , C07D265/18 , C07D275/06 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/06 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D519/00 , C07F5/025
Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-α enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-α signaling with the compounds and compositions of the disclosure.
-
公开(公告)号:US20230023559A1
公开(公告)日:2023-01-26
申请号:US17766885
申请日:2020-10-06
Applicant: D. E. Shaw Research, LLC
Inventor: Fabrizio GIORDANETTO , Morten Østergaard JENSEN , Vishwanath JOGINI , Roger John SNOW
IPC: C07D211/12 , C07D401/06 , C07D401/12 , C07D405/04 , C07D413/06 , C07D401/04 , C07D413/04 , C07D409/06 , C07D401/14 , C07D205/04 , C07D207/06 , C07D223/04 , C07D453/02 , C07D417/04
Abstract: A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
-
公开(公告)号:US11529347B2
公开(公告)日:2022-12-20
申请号:US16335933
申请日:2017-09-22
Applicant: Relay Therapeutics, Inc. , D. E. Shaw Research, LLC
Inventor: Brian K. Albrecht , Fabrizio Giordanetto , Jack Benjamin Greisman , Paul Maragakis , Alexander M. Taylor , W. Patrick Walters
IPC: A61K31/4985 , A61K31/55 , C07D487/04 , C07D519/00 , C07D498/10
Abstract: The present invention relates to novel compounds having the general formula: and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.
-
公开(公告)号:US20220340576A1
公开(公告)日:2022-10-27
申请号:US16950576
申请日:2020-11-17
Applicant: Relay Therapeutics, Inc. , D. E. Shaw Research, LLC
Inventor: Alexander M. Taylor , André Lescarbeau , Elizabeth H. Kelley , Kelley C. Shortsleeves , W. Patrick Walters , Mark Andrew Murcko , Thomas H. McLean , Hakan Gunaydin , Fabrizio Giordanetto , Eric Therrien
IPC: C07D487/04 , C07D401/04 , C07D401/14 , C07D519/00
Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
-
公开(公告)号:US12217834B2
公开(公告)日:2025-02-04
申请号:US17614856
申请日:2020-05-29
Applicant: D. E. Shaw Research, LLC
Inventor: Paul Maragakis , Hunter Nisonoff , Peter Skopp , John Salmon
Abstract: Discovering molecules (which may be known or may never have been cataloged or ever synthesized) that have desired characteristics is addressed using a machine learning approach. As compared to a brute-force search of a database of known molecules, which may not be computationally feasible, the present machine learning approach renders identification of both known and unknown molecules computationally tractable. Furthermore, the computational effort is largely shifted to training of the machine learning system using a database of known molecules, and the generation of molecules to match any particular characteristics requires relatively little computation. The molecules using the present approach may be further studied, for example, with computer-based simulation or after physical synthesis using biological experimentation to ultimately yield useful chemical compounds.
-
公开(公告)号:US12084447B2
公开(公告)日:2024-09-10
申请号:US16950576
申请日:2020-11-17
Applicant: Relay Therapeutics, Inc. , D. E. Shaw Research, LLC
Inventor: Alexander M. Taylor , André Lescarbeau , Elizabeth H. Kelley , Kelley C. Shortsleeves , W. Patrick Walters , Mark Andrew Murcko , Thomas H. McLean , Hakan Gunaydin , Fabrizio Giordanetto , Eric Therrien
IPC: C07D487/04 , C07D221/20 , C07D401/04 , C07D401/12 , C07D401/14 , C07D417/04 , C07D417/14 , C07D491/107 , C07D513/04 , C07D519/00
CPC classification number: C07D487/04 , C07D221/20 , C07D401/04 , C07D401/12 , C07D401/14 , C07D417/04 , C07D417/14 , C07D491/107 , C07D513/04 , C07D519/00
Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
-
公开(公告)号:US20240169124A1
公开(公告)日:2024-05-23
申请号:US18282818
申请日:2022-03-18
Applicant: D. E. Shaw Research, LLC
Inventor: Brannon Batson , Brian Lee Greskamp , Bruce Edwards , Jeffrey Adam Butts , Christopher Howard Fenton , Jeffrey Paul Grossman , Douglas John Ierardi , Adam Lerer , Brian Patrick Towles , Michael Edmund Bergdorf , Cristian Predescu , John K. Salmon , Andrew Garvin Taube
IPC: G06F30/25
CPC classification number: G06F30/25
Abstract: Improvements in a molecular-dynamic simulator provide ways to save energy during computation and reduce die area consumed on an integrated circuit. Examples of such improvements include different interaction modules for different ranges, the use of streaming along rows while multicasting along columns in an array of interaction modules, the selection of computation units based on balancing computational costs and communication costs, the use of fences in networks that connect computation units, and the use of bond calculators to carry out specialized bond calculations.
-
公开(公告)号:US11701354B2
公开(公告)日:2023-07-18
申请号:US16651733
申请日:2018-09-28
Applicant: Relay Therapeutics, Inc. , D. E. Shaw Research, LLC
Inventor: Alexander M. Taylor , W. Patrick Walters , Mark Andrew Murcko , Fabrizio Giordanetto , Eric Therrien , Sathesh Bhat , Markus Kristofer Dahlgren
IPC: A61K31/4985 , C07D487/04 , A61K45/06 , C07D519/00
CPC classification number: A61K31/4985 , A61K45/06 , C07D487/04 , C07D519/00
Abstract: Cellular biological activities are tightly controlled by intracellular signaling processes initiated by extracellular signals. Protein tyrosine phosphatases, which remove phosphate groups from tyrosine phosphorylated signaling molecules, play equally important tyrosine roles as protein kinases in signal transduction. SHP-2, a cytoplasmic SH2 domain containing protein tyrosine phosphatase, is involved in the signaling pathways of a variety of growth factors and cytokines. Recent studies have clearly demonstrated that this phosphatase plays an important role in transducing signal relay from the cell surface to the nucleus, and is a critical intracellular regulator in mediating cell proliferation and differentiation.
-
公开(公告)号:US11591336B2
公开(公告)日:2023-02-28
申请号:US16616361
申请日:2018-05-25
Applicant: Relay Therapeutics, Inc. , D. E. Shaw Research, LLC
Inventor: Alexander M. Taylor , André Lescarbeau , Elizabeth H. Kelley , Kelley C. Shortsleeves , Lucian V. DiPietro , W. Patrick Walters , Mark Andrew Murcko , Levi Charles Thomas Pierce , Yong Tang , Fabrizio Giordanetto , Jack Benjamin Greisman , Paul Maragakis , Sathesh Bhat , Markus Kristofer Dahlgren , Eric Therrien
IPC: A61K31/4985 , C07D487/04 , C07D519/00
Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
-
公开(公告)号:US20230049231A1
公开(公告)日:2023-02-16
申请号:US17766834
申请日:2020-10-06
Applicant: D. E. Shaw Research, LLC
Inventor: Fabrizio GIORDANETTO , Morten Østergaard JENSEN , Vishwanath JOGINI , Roger John SNOW
IPC: C07D471/04 , C07D401/02 , C07D405/02 , C07D413/02 , C07D487/04
Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, where the substituents are as defined herein. Pharmaceutical compositions including the same and method of using the same are also described.
-
-
-
-
-
-
-
-
-